<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348110</url>
  </required_header>
  <id_info>
    <org_study_id>CS19152</org_study_id>
    <nct_id>NCT04348110</nct_id>
  </id_info>
  <brief_title>Evaluation of Eye Health Benefits of Blueberry Chewable Tablets</brief_title>
  <official_title>Evaluation of Eye Health Benefits of Blueberry Chewable Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCI Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TCI Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of blueberry chewable tablets on Eye Health
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">March 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Schirmer's test</measure>
    <time_frame>8 weeks</time_frame>
    <description>Schirmer's test determines whether the eye produces enough tears to keep it moist. Units: mm (in 5minutes)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of tear meniscus height</measure>
    <time_frame>8 weeks</time_frame>
    <description>Slit lamp Ocular Surface Analyzer is utilized to measure tear meniscus height. Units: mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of non-invasive tear break-up time (NITBUT)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Ocular Surface Analyzer is utilized to measure non-invasive tear break-up time. Units: sec</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear break-up time (TBUT)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Slit lamp ocular Surface Analyzer is utilized to measure fist tear break-up time with slit lamp. Units: sec</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of accommodation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Speedy-I is utilized to measure the accommodative micro fluctuation test of the ciliary muscle. Units: HFC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Ocular Surface Disease Index (OSDI) is a 12-item scale for the assessment of symptoms related to dry eye disease and their effect on vision. Units: point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of eye pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Eye pressure is measured in millimeters of mercury (mm Hg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Intraocular pressure (IOP)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Eye pressure is measured in millimeters of mercury (mm Hg). Units: mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Near point of convergence (NPC)</measure>
    <time_frame>8 weeks</time_frame>
    <description>RAF rule were initiated in order to normalize NPC. Record as break/recovery. Units: cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Stereo vision</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Randot Stereotest is utilized to evaluate the depth perception. Units: sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of binocular motor fusion</measure>
    <time_frame>8 weeks</time_frame>
    <description>The test is utilized to evaluate to assess binocular motor fusion, specifically the extent to which a patient can maintain binocular single vision (BSV) in the presence of increasing vergence demands. Units: prism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Amplitude of accommodation (AA)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The amplitude of accommodation is the maximum potential increase in optical power that an eye can achieve in adjusting its focus. It refers to a certain range of object distances for which the retinal image is as sharply focused as possible. Units: diopter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Amplitude of Flipper facility</measure>
    <time_frame>8 weeks</time_frame>
    <description>Vergence facility (VF) was measured by using a prism flipper to evaluate the ability of the fusional vergence at near with +/-2.00 flipper. Units: cpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Fundus photography</measure>
    <time_frame>8 weeks</time_frame>
    <description>The fundus is the back of the eye and includes the retina, optic nerve, and retinal blood vessels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Eye</condition>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Blueberry Chewable Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>consume 2 tablets per day for 8 weeks</description>
    <arm_group_label>Placebo tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry Chewable Tablets</intervention_name>
    <description>consume 2 tablets per day for 8 weeks</description>
    <arm_group_label>Blueberry Chewable Tablets</arm_group_label>
    <other_name>NutraViewÂ® Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women over 20 years old

          -  Use 3C products over 6 hours per day

          -  Symptoms of dry eyes or tired eyes

          -  Tear Break-Up Time is 10 seconds less

          -  No history of ocular surgery (strabismus surgery, refractive surgery etc.)

        Exclusion Criteria:

          -  Have systemic diseases affecting the front surface of the eyes.

          -  Long-term use of drugs or eye drops that affect the condition of the front surface of
             the eyes

          -  Long-term contact lens wear
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo-Yie Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo-Yie Chen</last_name>
    <phone>+886-04-24730022</phone>
    <phone_ext>11708</phone_ext>
    <email>boychen@csmu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chung Shan Medical University</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo-Yie Chen</last_name>
      <phone>+886-04-24730022</phone>
      <phone_ext>11708</phone_ext>
      <email>boychen@csmu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

